Multidisciplinary Perspectives and Patient-Centered Approaches in Newly Diagnosed Multiple Myeloma

Program Description

The selection of drugs and recommended treatment protocols for each stage of multiple myeloma (MM) varies depending on factors such as patient age, overall health status, disease characteristics, and eligibility for high-dose chemotherapy and stem cell transplantation. Despite the wide range of available drugs for MM, the most effective selection and sequencing strategy remains unclear. The introduction of quadruplet therapy regimens marks a significant advancement in the treatment of patients with newly diagnosed MM. As this new strategy evolves as a frontline treatment option in MM, maintaining familiarity with clinical guideline recommendations may be challenging for oncology pharmacists when identifying patients who are most likely to benefit from these regimens. This multidisciplinary panel discussion will cover the emergence of quadruple therapy regimens for patients with newly diagnosed MM as well as education about supportive care and prophylactic measures to mitigate treatment-related adverse effects. Informed by social media analytic tools and insights about discussion points from patients, caregivers, and health care professionals regarding treatment of MM gathered through artificial intelligence technology, the interactive format of this program features opportunities for panelists to debate and discuss the challenges and trends in management of newly diagnosed MM. Participants will be able to provide responses to the discussion in real-time.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: December 23, 2024
Expiration date: December 23, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the recent advances in newly diagnosed multiple myeloma treatment as it relates to quadruplet induction therapy
• Examine disease risk criteria to identify patients that benefit most from quadruplet induction therapy
• Implement strategies to minimize treatment-related adverse effects

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-352-H01-P. The activity is available for CE credit through December 23, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose:

Consultant: Janssen, Pfizer, Sanofi, Genmab, Genentech

Joseph A. Kalis, PharmD, BCOP; and Anthony Dominick, DO, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

View Slides